ophthalmia%20neonatorum
OPHTHALMIA NEONATORUM
Ophthalmia neonatorum is conjunctivitis occurring in a newborn during the first month of life.
It is also called neonatal conjunctivitis.
Organisms causing neonatal conjunctivitis are usually acquired from the infected birth canal of the mother during vaginal delivery, though some may acquire the infection from their immediate surroundings.
It is one of the leading cause of blindness in infants via corneal ulceration and subsequent opacification or perforation and endophthalmitis.

Ophthalmia%20neonatorum Patient Education

Patient Education

  • When appropriate, explain the natural history of the disease & the importance of prevention
  • Educate parents or caregiver to wash their hands frequently to prevent transmission of neonatal conjunctivitis
  • Educate pregnant women on:
    • The importance of having regular prenatal check up & prenatal care as prophylaxis
    • The importance of treating sexually transmitted infections to decrease the incidence of ophthalmia neonatorum
  • Emphasize the importance of treating the mother & her sexual partner(s) as usually the causative organism is sexually transmitted
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 6 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.